A Study to Evaluate LY3154207 on the Brain of Healthy Participants

The purpose of this study is to learn more about how LY3154207 affects the brain of healthy participants by using magnetic resonance imaging. The study will last up to about nine weeks for each participant and may include up to four visits to the study center.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Northwestern University

Chicago, Illinois, 60659, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-Overtly healthy males and non-childbearing females, as determined through medical history and physical examination

Exclusion criteria

Have known or ongoing psychiatric disorders
Have contraindications to magnetic resonance imaging (MRI)

Treatment and study plan

LY3154207

Drug

LY3154207 administered orally.

Placebo

Drug

Placebo administered orally.

Primary outcomes

Change from Baseline in Intrinsic Functional Connectivity Among Resting-State Networks of the Brain

Time frame: Day 1, Approximately Day 28

Mean Connectivity and Mean Component Weight Between LY3154207 and Placebo in the Dorsal Attention Network (DAN), Frontoparietal Network (FPN), and Executive Control Network (ECN).

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Single-Dose Study Using Functional Magnetic Resonance Imaging to Evaluate the Effect of LY3154207 in Healthy Subjects

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Feb 6, 2020
Registry last updated: Feb 22, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed